Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025
Adaptive Biotechnologies (Nasdaq: ADPT), a commercial stage biotechnology company focused on translating adaptive immune system genetics into clinical products, has scheduled its Q1 2025 financial results announcement for May 1, 2025, after market close.
The company will host a conference call and webcast at 1:30 PM Pacific Time / 4:30 PM Eastern Time on the same day. Investors can access the live audio webcast through the company's website investor section, with a replay available within 24 hours after the event.
Adaptive Biotechnologies (Nasdaq: ADPT), un'azienda biofarmaceutica in fase commerciale focalizzata sulla traduzione della genetica del sistema immunitario adattivo in prodotti clinici, ha programmato l'annuncio dei suoi risultati finanziari del Q1 2025 per il 1° maggio 2025, dopo la chiusura del mercato.
L'azienda ospiterà una conferenza telefonica e un webcast alle 13:30 ora del Pacifico / 16:30 ora dell'Est nello stesso giorno. Gli investitori possono accedere al webcast audio dal vivo attraverso la sezione investitori del sito web dell'azienda, con una registrazione disponibile entro 24 ore dopo l'evento.
Adaptive Biotechnologies (Nasdaq: ADPT), una empresa de biotecnología en etapa comercial centrada en traducir la genética del sistema inmunológico adaptativo en productos clínicos, ha programado el anuncio de sus resultados financieros del Q1 2025 para el 1 de mayo de 2025, después del cierre del mercado.
La empresa llevará a cabo una conferencia telefónica y un webcast a la 1:30 PM hora del Pacífico / 4:30 PM hora del Este el mismo día. Los inversores pueden acceder al webcast de audio en vivo a través de la sección de inversores del sitio web de la empresa, con una repetición disponible dentro de las 24 horas posteriores al evento.
Adaptive Biotechnologies (Nasdaq: ADPT)는 적응 면역 체계 유전자를 임상 제품으로 전환하는 데 중점을 둔 상업 단계 생명공학 회사로, 2025년 1분기 재무 결과 발표를 2025년 5월 1일 시장 종료 후로 예정했습니다.
회사는 같은 날 태평양 표준시 기준 오후 1시 30분 / 동부 표준시 기준 오후 4시 30분에 전화 회의 및 웹캐스트를 개최할 것입니다. 투자자들은 회사 웹사이트의 투자자 섹션을 통해 실시간 오디오 웹캐스트에 접근할 수 있으며, 이벤트 후 24시간 이내에 다시 볼 수 있는 서비스도 제공됩니다.
Adaptive Biotechnologies (Nasdaq: ADPT), une entreprise de biotechnologie en phase commerciale axée sur la traduction de la génétique du système immunitaire adaptatif en produits cliniques, a prévu l'annonce de ses résultats financiers du Q1 2025 pour le 1er mai 2025, après la fermeture du marché.
L'entreprise organisera une conférence téléphonique et un webcast à 13h30 heure du Pacifique / 16h30 heure de l'Est le même jour. Les investisseurs peuvent accéder au webcast audio en direct via la section investisseurs du site web de l'entreprise, avec une rediffusion disponible dans les 24 heures suivant l'événement.
Adaptive Biotechnologies (Nasdaq: ADPT), ein biotechnologisches Unternehmen in der kommerziellen Phase, das sich darauf konzentriert, die Genetik des adaptiven Immunsystems in klinische Produkte zu übersetzen, hat die Bekanntgabe seiner Finanzergebnisse für das 1. Quartal 2025 für den 1. Mai 2025 nach Börsenschluss angesetzt.
Das Unternehmen wird am selben Tag um 13:30 Uhr pazifischer Zeit / 16:30 Uhr östlicher Zeit eine Telefonkonferenz und einen Webcast veranstalten. Investoren können über den Investorenbereich der Unternehmenswebsite auf den Live-Audio-Webcast zugreifen, und eine Wiederholung wird innerhalb von 24 Stunden nach der Veranstaltung verfügbar sein.
- None.
- None.
SEATTLE, April 10, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 1, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the “Investors” section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours after the event.
About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
investors@adaptivebiotech.com
ADAPTIVE MEDIA
Erica Jones, Associate Director, Corporate Communications
845-344-7542
media@adaptivebiotech.com
FAQ
When will Adaptive Biotechnologies (ADPT) release Q1 2025 earnings?
What time is Adaptive Biotechnologies (ADPT) Q1 2025 earnings call?
How can investors access ADPT's Q1 2025 earnings call?
Will ADPT's Q1 2025 earnings call be available for replay?
